These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17484271)

  • 1. Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer.
    Prayer-Galetti T; Gardiman M; Sacco E; Fracalanza S; Betto G; Pinto F
    Anal Quant Cytol Histol; 2007 Apr; 29(2):79-86. PubMed ID: 17484271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.
    Köllermann J; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Hopfenmüller W; Helpap B
    Urology; 2003 Sep; 62(3):476-80. PubMed ID: 12946750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
    Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
    BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant hormonal therapy versus surgery alone for radical prostatectomy in high-risk prostate cancer patients].
    Kobayashi M; Saito Y; Komaru A; Fukasawa S; Suyama T; Akakura K; Ichikawa T; Ueda T
    Hinyokika Kiyo; 2013 Jul; 59(7):411-8. PubMed ID: 23945319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
    Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
    Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy.
    Moreira DM; Gershman B; Rangel LJ; Boorjian SA; Thompson RH; Frank I; Tollefson MK; Gettman MT; Karnes RJ
    BJU Int; 2016 Sep; 118(3):379-83. PubMed ID: 26305996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pT0 stage of prostate cancer be predicted before radical prostatectomy?
    Descazeaud A; Zerbib M; Flam T; Vieillefond A; Debré B; Peyromaure M
    Eur Urol; 2006 Dec; 50(6):1248-52; discussion 1253. PubMed ID: 16828964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
    Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
    J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
    Köllermann J; Hopfenmüller W; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Helpap B
    Eur Urol; 2004 Jan; 45(1):42-5. PubMed ID: 14667514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nondetectable prostate cancer in radical prostatectomy specimens].
    Murányi M; Morshed AS; Benyó M; Tóth C; Flaskó T
    Orv Hetil; 2012 Jan; 153(3):113-7. PubMed ID: 22236417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.